



## Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017

September 12, 2017

DUBLIN, Sept. 12, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company was named to Fortune magazine's list of fastest growing companies for 2017. In Fortune's annual rankings, Jazz was named the [78<sup>th</sup> fastest growing company](#).

"We are honored to be recognized with some of the most innovative companies in the world," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "Our continued growth is a testament to our hard-working, talented employees who are dedicated to bringing innovative therapies to market for life-threatening or complex conditions that have few if any treatment options."

Fortune magazine's 100 fastest-growing companies are publicly traded companies ranked by revenue growth rate, EPS growth rate and three-year annualized total return for the period ended June 30, 2017. The overall rank is based on the sum of these three ranks.

Jazz – which was recognized by Fortune as the [fastest growing company in 2013](#) – is a rapidly growing international biopharmaceutical company that is investing in optimizing the growth of its key products and advancing and expanding its R&D pipeline with a goal of bringing new therapeutic options to patients.

### About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem<sup>®</sup> (sodium oxybate) oral solution, Erwinaze<sup>®</sup> (asparaginase *Erwinia chrysanthem*), Defitelio<sup>®</sup> (defibrotide sodium) and Vyxeos<sup>™</sup> (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinaze<sup>®</sup> and Defitelio<sup>®</sup> (defibrotide) in countries outside the U.S. For more information, please visit [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

### "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' investing in optimizing the growth of its key products and advancing and expanding its R&D pipeline with a goal of bringing new therapeutic options to patients, and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: effectively commercializing the company's products and product candidates; the regulatory approval process; pharmaceutical product development and the uncertainty of clinical success; and the ability to achieve expected future financial performance and results; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and future filings and reports by the company, including the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.



View original content with multimedia: <http://www.prnewswire.com/news-releases/fortune-magazine-names-jazz-pharmaceuticals-78th-fastest-growing-company-for-2017-300517764.html>

SOURCE Jazz Pharmaceuticals plc

Media Contact: Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations, Ireland +353 1 697 2141, U.S. +1 215 867 4910, OR  
Investor Contact: Kathee Littrell, Vice President, Investor Relations, Ireland +353 1 634 7887, U.S. +1 650 496 2717